Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.

IF 5 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Psychopharmacology Pub Date : 2026-05-27 eCollection Date: 2026-01-01 DOI:10.1177/20451253261450772

Xiaoqian Lan, Hongyan Zhuang, Pengfei Li

{"title":"Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.","authors":"Xiaoqian Lan, Hongyan Zhuang, Pengfei Li","doi":"10.1177/20451253261450772","DOIUrl":null,"url":null,"abstract":"Background: The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.Objectives: To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.Design: This study was a single-arm retrospective cohort study.Methods: We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired t-test was used to compare PRL values before (⩽7 days, PRL1) and after (⩾7 days, PRL2) aripiprazole initiation.Results: The difference between PRL1 and PRL2 was not statistically significant (mean difference = 4.115 ng/ml, 95% CI (-5.121, 13.351) ng/ml, SD = 15.284, p = 0.351, Cohen's d = 0.269, 95% CI for d (-0.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups (p > 0.05). None of the leave-one-out analyses altered the study's conclusions (all p-values > 0.05), indicating that the results were not driven by any single extreme value.Conclusion: In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261450772"},"PeriodicalIF":5.0000,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253261450772","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.

Objectives: To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.

Design: This study was a single-arm retrospective cohort study.

Methods: We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired t-test was used to compare PRL values before (⩽7 days, PRL1) and after (⩾7 days, PRL2) aripiprazole initiation.

Results: The difference between PRL1 and PRL2 was not statistically significant (mean difference = 4.115 ng/ml, 95% CI (-5.121, 13.351) ng/ml, SD = 15.284, p = 0.351, Cohen's d = 0.269, 95% CI for d (-0.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups (p > 0.05). None of the leave-one-out analyses altered the study's conclusions (all p-values > 0.05), indicating that the results were not driven by any single extreme value.

Conclusion: In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.

查看原文本刊更多论文

辅助阿立哌唑治疗氨硫脲诱导的高泌乳素血症：一项初步回顾性研究显示无逆转作用。

背景：阿立哌唑逆转氨硫脲诱导的高泌乳素血症的潜力尚未确定。目的：探讨阿立哌唑辅助治疗是否能逆转氨硫脲诱导的催乳素升高。设计：本研究为单臂回顾性队列研究。方法：我们对一家三级专科精神病院于2022年6月1日至2025年12月31日期间接受氨硫pride治疗的患者的病历进行了回顾性分析，这些患者随后接受了阿立哌唑辅助治疗。数据通过电子病历系统收集。配对t检验用于比较阿立哌唑起始之前（≤7天，PRL1）和之后（大于或等于7天，PRL2）的PRL值。结果：PRL1与PRL2的差异无统计学意义(平均差异= 4.115 ng/ml, 95% CI （-5.121, 13.351) ng/ml, SD = 15.284, p = 0.351, Cohen’SD = 0.269, 95% CI为d(-0.290, 0.818)）。性别和诊断的分层分析结果与各亚组的主要分析一致（p < 0.05）。所有的“留一”分析都没有改变研究的结论（所有的p值都是0.05），这表明结果不是由任何一个极端值驱动的。结论：在阿米苏普利相关性高泌乳素血症患者中，本回顾性研究提示辅助用药阿立哌唑对逆转PRL升高的疗效不显著。因此，在获得更全面的研究证据之前，在临床实践中应谨慎使用辅助阿立哌唑逆转氨硫脲诱导的PRL升高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Psychopharmacology Multiple-

CiteScore

7.90

自引率

2.40%

发文量

审稿时长

10 weeks

期刊介绍： Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.